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POPULATION PHARMACOKINETICS OF INTRAVENOUS 
VALPROIC ACID IN KOREAN PATIENTS. D.  Yim~ MD, PhD, 
H. Park, MD, College of Med. The Catholic Univ. of Korea, Gachon 
Medical School, Seoul, Korea. 
Purpose. To determine population-based pharmacokinetic param- 
eters for intravenous valproic acid, and the factors influencing these 
parameters, in Korean adults. 
Methods. Valproic acid concentrations were obtained using a peak 
and trough sampling scheme for 102 Korean epileptic patients who 
were not taking concurrent antiepileptic medication. Three hundred 
and fifty-four serum concentrations were analyzed according to a 
one-compartment model with a mixed effect modeling method 
(NONMEM Ver 5.0). The influence of body-weight (kg), height, 
daily valproic acid close (mg/day), body mass index (kg/m2), sex, and 
age on Vd and CL was assessed in the course of analysis. 
Results. Vd and CL of valproic acid increased with body-weight. 
No significant influence of the other screened covariates was ob- 
served. The final regression model was: 
CL (L/h) = 0.849 × (body-weight / 60) °.7o2 
Vd (L) = 15.1 × (body-weight / 60) °6°4 
Interindividual variabilities (coefficient of variation) for CL and 
Vd were 32% and 18%, respectively. Residual error including intra- 
individual variability was 26.7%. 
Conclusion. The current results may be used as a basic reference 
to optimize drug therapy with intravenous valproic acid. Further 
research on the pediatric population is necessary to confirm the 
nonlinearity of the relation between body-weight and Vd. 
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SAFETY AND TOLERABILITY AND ABSORPTION OF TOP- 
ICAL THALIDOMIDE. S .M.  Gordon, DDS, M ~  S. M. Wahl, 
PhD, C. Picco, BS, R. A. Dionne, DDS, PhD, NIH, NIDCR, Be- 
thesda, MD. 
The adverse effects of thalidomide are well known, but there are 
no published data on the safety, tolerability, and absorption of low 
doses delivered by the topical route. This study evaluated the safety 
and tolerability of topical thalidomide applied to oral mucosa and 
determined the amount of drug reaching systemic circulation. Sub- 
jects were HIV+ pts with oral ulcers and age-matched healthy 
volunteers receiving 0, 5, 10, or 20 mg topical thalidomide applied to 
intact buccal mucosa in a randomized, double-blind design. Blood 
drawn serially was measured for thalidomide by HPLC using UV 
detection. The 20 mg dose was detectable in plasma 5 rain post 
application and peaked at 1 hr in H1V+ pts with oral ulcers, whereas 
the same dose was detectable only at 3 hr in healthy volunteers. The 
remaining doses were below the level of reliable quantitation. The 
difference in detection of 20 mg of topical thalidomide in the healthy 
subjects versus the HIV+ pts with oral ulcers indicates that drug 
absorption was facilitated by the inflamed and disrupted mucosa. 
There were no significant differences in side effects between placebo 
and any dose group. Viral load did not change in HIV+ pts over the 
course of several weeks of treatment and there was no incidence of or 
change in neuropathy. The low plasma concentration and negligible 
incidence of adverse effects in both subject groups suggests topical 
thalidomide may be active at a lower dose while minimizing absorp- 
tion and adverse effects. 
PDI-A-1 
LACK OF GENOTYPE:PHENOTYPE ASSOCIATIONS BE- 
TWEEN CYP3A4*IB, CYP3A5*3C, CYP3A5*6 AND MIDAZO- 
LAM METABOLISM 1N EUROPEAN- AND AFRICAN- 
AMERICANS. M. Floyd, MD, G. Gervasini, PbD, K. Bhat, PhD, A. 
George, MD, G. Mayo, RN, G. R. Wilkinson, PhD, DSc, G. Wilkin- 
son, PhD, DSc, Vanderbilt University, Nashville, TN. 
The determinants of interindividual variability in basal and in- 
duced CYP3A activity are unclear. Identification of common genetic 
variants, some with functional consequences, suggest a possible 
molecular mechanism. Thus, midazolam's disposition after intrave- 
nous and oral administration was determined in 70 healthy subjects, 
substratified about equally according to sex and racial ancestry 
(European- versus African-American), genotyped for 
CYP3A4*IB, CYP13AS*3C and CYP3AS*6 alleles. Studies were per- 
formed prior to and after 21 days administration of rifampin (600 mg 
daily). Neither sex- nor population-related differences in midazo- 
lam's clearances were observed with either route, before or after 
rifampin treatment. Also, no differences in midazolam's clearances 
were noted between any homozygous wild-type or mutant groups and 
no gene-dose effects were observed for any of the variants. Rifampin 
treatment produced marked induction, however, its extent did not 
appear to be related to any specific genotype. It, therefore, appears 
that the studied genetic variants are not contributory to intersubject 
variability in CYP3A activity (supported by GM31304). 
PDI-A-2 
CORRELATION OF PHARMACOGENETIC GENOTYPE 
WITH STEADY-STATE METABOLIC PROFILES OF TAMOX- 
IFEN: EFFECT ON ACTIVE METABOLITE CONCENTRA- 
TIONS. _K. Lee, MD, PhD, Z. Desta, PhD, V. Stearns, MD, D. F. 
Hayes, MD, D. R. Jones, PhD, D. A. Flockhart, MD, PhD, 
Sungkyunkwau University College of Medicine, Samsung Medical 
Center, Indiana University, School of Medicine, University of Mich- 
igan, Suwon, Korea. 
To test the hypothesis that pharmacogenetic factors might alter 
tamoxifen (TAM) metabolism to active metabolites, a prospective 
clinical trial was conducted in 28 women who were taking oral 
tamoxifen (20mg/day) chronically tot the treatment or prevention of 
breast cancer. TAM and its metabolites were measured in plasma 
after 4 months of the drug administration by high-performance liquid 
chromatography with on-line derivatization and genotypes for 
CYP2C9 (*2 and *3), CYP2C19 (*2 and *3), CYP2D6 (*3, *4, *6, 
*8, *10, and "17), and CYP3A5 (*3 and *6) were determined. The 
genotypes for CYP2C9, CYP3A5, and CYP2CI9 did not correlate 
separately, or in any combination with plasma concentrations of" 
TAM or its metabolites. In contrast, the concentrations of 4-hydroxy- 
N-desmethyltamoxifen (4-OH-NDM) was significantly lower 
(p=0.0003) in the subjects (n=8) with CYP2D6*I/*4, CYP2D6*I/ 
*6, or CYP2D6*4/*4 genotype compared with those in 
CYP2D6*I/*I or CYP2D6*I/*t0 genotype (n=20). Accordingly, 
the molar concentration ratios of 4-OH-NDM/NDM and 4-OH- 
NDM/TAM in the subjects who have CYP2D6*4 or CYP2D6*6 
variant allele(s) were significantly lower compared with those in 
CYP2D6* 1/* 1 or CYP2D6* 1/* 10 ( p :  0.0061 and p = 0.0010, respec- 
tively). In addition, the molar concentration ratio of 4-OH-NDM/4- 
OH-TAM in the subjects who have CYP2D6*4 or CYP2D6*6 variant 
allele(s) were significantly higher compared with those in 
CYP2D6* t/* 1 or CYP2D6* t/* 10 (p = 0.0002). 
